Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2995
Gene Symbol: GYPC
GYPC
0.020 GeneticVariation disease BEFREE Our objective was to use Mendelian randomization to evaluate whether SZ increased risk for developing EOC or the converse, and, whether SZ impacted 1- or 2-glycerophosphocholine (1- or 2-GPC) metabolites. 31844628 2019
Entrez Id: 100505881
Gene Symbol: MAGI2-AS3
MAGI2-AS3
0.010 Biomarker disease BEFREE After analyzing the trend in HGSC and other cancers, MAGI2-AS3 was observed to be an important player in EOC. 31842477 2019
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 GeneticVariation disease BEFREE Specifically, mutations of CTNNB1, AXIN, or APC, have been observed in the endometrioid and mucinous subtypes of EOC. 31829231 2019
Entrez Id: 324
Gene Symbol: APC
APC
0.020 Biomarker disease BEFREE Specifically, mutations of CTNNB1, AXIN, or APC, have been observed in the endometrioid and mucinous subtypes of EOC. 31829231 2019
Entrez Id: 607
Gene Symbol: BCL9
BCL9
0.010 AlteredExpression disease BEFREE Thus, in this research, we aimed to investigate the expression and clinical significance of BCL9 in EOC tissues and its effect on the malignant biological behavior of human ovarian cancer cells. 31827404 2019
Entrez Id: 2308
Gene Symbol: FOXO1
FOXO1
0.020 AlteredExpression disease BEFREE FOXO1 and PAX3 protein expression levels were significantly higher in EOC tissues than in nonadjacent normal epithelial tissues, benign tissues, and borderline tumors (all p < 0.001). 31823759 2019
Entrez Id: 5077
Gene Symbol: PAX3
PAX3
0.010 AlteredExpression disease BEFREE FOXO1 and PAX3 protein expression levels were significantly higher in EOC tissues than in nonadjacent normal epithelial tissues, benign tissues, and borderline tumors (all p < 0.001). 31823759 2019
Entrez Id: 8405
Gene Symbol: SPOP
SPOP
0.010 AlteredExpression disease BEFREE Our results from the present study indicated that SPOP expression was significantly downregulated in human epithelial ovarian cancer and was associated with the FIGO stage and the histopathologic grading of the tumor. 31819473 2019
Entrez Id: 9058
Gene Symbol: SLC13A2
SLC13A2
0.040 Biomarker disease BEFREE Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer. 31818526 2019
Entrez Id: 284111
Gene Symbol: SLC13A5
SLC13A5
0.040 Biomarker disease BEFREE Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer. 31818526 2019
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.100 Biomarker disease BEFREE In summary, we show here that the pro-angiogenic effect of NGF in EOC depends on the COX-2/PGE2 signaling axis. 31817839 2019
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
0.080 Biomarker disease BEFREE Thus, inhibition COX-2/PGE2 signaling will likely be beneficial in the treatment of EOC. 31817839 2019
Entrez Id: 107075310
Gene Symbol: MTCO2P12
MTCO2P12
0.050 Biomarker disease BEFREE Thus, inhibition COX-2/PGE2 signaling will likely be beneficial in the treatment of EOC. 31817839 2019
Entrez Id: 4513
Gene Symbol: COX2
COX2
0.050 Biomarker disease BEFREE Thus, inhibition COX-2/PGE2 signaling will likely be beneficial in the treatment of EOC. 31817839 2019
Entrez Id: 3949
Gene Symbol: LDLR
LDLR
0.010 Biomarker disease BEFREE Relatedly, LDLR expression could serve as a biomarker of chemotherapy sensitivity in EOCs. 31815680 2020
Entrez Id: 406996
Gene Symbol: MIR214
MIR214
0.030 Biomarker disease BEFREE Collectively, we suggest that miR-214-3p in serum exosomes can be a potential biomarker for the diagnosis and prognosis of ovarian tumor, and its inhibition can be a supportive treatment for EOC. 31810245 2019
Entrez Id: 26468
Gene Symbol: LHX6
LHX6
0.010 AlteredExpression disease BEFREE We also analyzed the mRNA levels of target genes that candidate miRNAs might regulate in patient tissues. miR-214-3p was highly expressed in tissues and exosomes derived from EOC with high malignancy and also found to regulate the expression of LIM homeobox domain 6 (LHX6) mRNA. 31810245 2019
Entrez Id: 10611
Gene Symbol: PDLIM5
PDLIM5
0.010 AlteredExpression disease BEFREE We also analyzed the mRNA levels of target genes that candidate miRNAs might regulate in patient tissues. miR-214-3p was highly expressed in tissues and exosomes derived from EOC with high malignancy and also found to regulate the expression of LIM homeobox domain 6 (LHX6) mRNA. 31810245 2019
Entrez Id: 1453
Gene Symbol: CSNK1D
CSNK1D
0.010 Biomarker disease BEFREE Casein kinase 1 delta (CK1δ) has a tumor-promoting role in different cancers and it is genetically amplified in a portion of human epithelial ovarian cancer (EOC). 31799185 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). 31797087 2020
Entrez Id: 6938
Gene Symbol: TCF12
TCF12
0.010 Biomarker disease BEFREE These results indicated that miR‑26a may act as a tumor suppressor in OC, and TCF12 targeting by miR‑26a may be a new therapeutic strategy for OC. 31789414 2020
Entrez Id: 6774
Gene Symbol: STAT3
STAT3
0.090 AlteredExpression disease BEFREE Targeting the activation of Stat3 may be a potential therapeutic approach for EOC by acting synergistically with paclitaxel. 31778258 2020
Entrez Id: 1022
Gene Symbol: CDK7
CDK7
0.020 Biomarker disease BEFREE Mechanistic interrogation of CDK7 revealed that it is significantly associated with an aggressive phenotype of EOC, and it has independent prognostic power for EOC recurrence. 31776040 2020
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.100 Biomarker disease BEFREE SFRP1 inhibited epithelial ovarian cancer through inhibiting Wnt/β-catenin pathway, suggesting that SFRP1 could be considered as a potential therapeutic target in epithelial ovarian cancer. 31770484 2019
Entrez Id: 6422
Gene Symbol: SFRP1
SFRP1
0.020 Biomarker disease BEFREE The aim of this research was to investigate the effects and the mechanism of action of SFRP1 on epithelial ovarian cancer. 31770484 2019